Effects of synthetic colloids on oxidative stress and inflammatory response in hemorrhagic shock: comparison of hydroxyethyl starch 130/0.4, hydroxyethyl starch 200/0.5, and succinylated gelatin

Hemorrhagic shock (HS) is the leading cause of death in civilian and military trauma [1, 2]. Initial survivors of HS are particularly susceptible to the systemic inflammatory response syndrome (SIRS), which triggers multiple organ failure (MOF) and post-traumatic death [3‐5]. The pathogenesis of multiple organ failure remains elusive, but the oxidative stress and systemic inflammation that are induced by hemorrhagic shock/fluid resuscitation (HS/R) contribute to the occurrence of MOF [6, 7].

Fluid resuscitation is a common intervention for the management of HS victims to maintain organ perfusion, particularly on the battlefield. However, fluid resuscitation may contribute to oxidative stress and inflammation due to reperfusion injury. Oxidative stress induced by reactive oxygen species (ROS) may directly damage cellular membranes via lipid peroxidation. Oxidative stress also initiates systemic inflammatory cascades through the enhancement of neutrophil activation [8]. Activated neutrophils release cytotoxic ROS, proteases and elastases which produce tissue injury, an enhanced systemic inflammatory response and MOF [9, 10]. Therefore, ideal resuscitation strategies should suppress oxidative stress and the systemic inflammatory response after HS in addition to maintaining effective organ perfusion. Colloid solutions are widely used for the prevention and correction of hypovolemia in clinical fluid management. However, direct comparisons of oxidative stress and the inflammatory response after commonly used synthetic colloid infusions in hemorrhagic shock are lacking.

Our understanding of the important role of resuscitation fluids in the pathogenesis of MOF raises questions on the effect of widely used colloid fluids in the suppression of oxidative stress and the inflammatory response in vital tissues. We hypothesized that oxidative stress and the inflammatory response is influenced by the choice of colloid solutions. Hydroxyethyl starch (HES), gelatin (GEL), and dextrans are commonly used synthetic colloids [11, 12]. HES 130, HES 200, succinylated GEL, and dextran 70 are four representative products. The present study in a rat HS model compared HES 130, HES 200, and GEL to demonstrate their relative therapeutic benefits in the amelioration of HS/R-induced oxidative stress and the inflammatory response. Dextran 70 was not included in this experiment because it is not tolerated by rats [13, 14]. Malondialdehyde (MDA), which is a product of lipid peroxidation, was measured to determine the oxidative stress in tissues in this study. Myeloperoxidase (MPO) activity was measured to determine neutrophil sequestration in tissues [15]. The levels of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in the intestine were also measured.

The present study demonstrated that HES 130 infusion suppressed oxidative stress and the inflammatory response in a rodent model of controlled hemorrhage compared to HES 200 and GEL. No significant differences were observed between HES 200 and GEL.

Prolonged organ ischemia due to hemorrhagic shock may lead to death. Therefore, early aggressive fluid resuscitation for adequate tissue and cellular perfusion has been the therapeutic norm in hemorrhagic shock patients. However, this notion has been challenged recently [17]. Laboratory efforts directed toward the discovery of the ideal resuscitative fluid have emerged from an understanding of hemorrhagic shock as a disease of decreased perfusion and altered immunity. Therefore, research efforts aimed at the identification of treatments for hemorrhagic shock have targeted volume restoration and the prevention and amelioration of the immune and inflammatory effects of hemorrhage [18]. Crystalloids differentially influence hemorrhage-induced oxidative stress and inflammatory responses through the upregulation of ROS generation and neutrophil activity [10, 19].

HES solutions are synthetic colloids that are widely used to maintain or improve tissue perfusion in HS treatment. However, the pharmacology of HES varies greatly between solutions depending on their characteristics, including molecular weight, the degree of hydroxyethyl substitution and the C2/C6 ratio of hydroxyethylation [20]. HES 200 and HES 130 solutions are commonly used HES solutions. Blood loss and transfusion requirements are significantly reduced in major surgery when HES 130 is administered compared to HES 200 [21, 22]. Furthermore, platelet dysfunction exhibits a faster recovery after the infusion of HES 130 compared to HES 200 [23]. However, little is known about the effects of the two different HES solutions on oxidative stress and the inflammatory response following HS/R.

HES 200 decreases the plasma levels of coagulation factor VIII and von Willebrand factor; this produces coagulation impairment [21, 24] and bleeding events [25] compared to HES 130. Extensive cross-talk is observed between inflammation and hemostasis [26]. Vancine et al. demonstrated that factor VIII deficiency is associated with higher inflammatory levels after a lipopolysaccharide (LPS) challenge [27]. This result suggests that the impairment in the blood coagulation system results in a relatively poor anti-oxidative and anti-inflammatory effect following HS/R for HES 200. Moreover, the advantages of HES 130 may be due to improvements in tissue oxygen [28] due to its hemorheological advantages over HES 200 [29]. Our results partially confirmed a previous study. Huter et al. demonstrated that 6% HES 130/0.42, which is another rapidly degradable HES solution with low molecular weight and degree of substitution, significantly reduces macrophage infiltration and interstitial cell proliferation compared to 10% HES 200/0.5 in an isolated kidney perfusion model [30].

HES 200 exhibits anti-inflammatory effects in vivo and in vitro [31‐34]. In an HS model, a 20 mL/kg HES 200 infusion inhibits the inflammatory response following HS/R compared to GEL [17]. Tsai et al. demonstrated that resuscitation using 8 mL/kg HES 200 prevents oxidative stress and nuclear factor-kappa B (NF-κB) activation [35]. HES 200 attenuates cell injury in inflammatory-stimulated tubular epithelial cells in vitro [31]. However, these results are not consistent with our observations. We did not observe any differences in oxidative stress and inflammatory responses between the GEL and HES 200 groups. The infusion dose may account for these controversial results. Approximately 33 mL/kg of the colloid solutions were used in this study, which is the recommended maximum dose for HES 200, but it is far less than the recommended maximum daily dose of HES 130 (50 mL/kg) [36]. Tian et al. demonstrated that a lower dose of HES 200 (3.75 and 7.5 mL/kg) significantly suppresses LPS-induced NF-κB activation in four tissues (lungs, liver, heart, and kidneys). However, 15 mL/kg HES 200 inhibits NF-κB activity only in the lungs and liver, and 30 mL/kg HES 200 exerts no effect in any measured organs [35, 37]. The effect of GEL on the inflammatory response was similar at three doses (7.5, 15 and 30 mL/kg) [38]. These results indicate that the anti-inflammatory effect of HES 200 is volume-dose dependent. A large infusion dose may inhibit the anti-inflammatory effects of HES 200, which produces similar oxidative stress and inflammatory responses between the GEL and HES 200 groups. Future studies are required to delineate the underlying mechanism.

The comparison of the impact of HES 130 and GEL on oxidative stress and the inflammatory response in hemorrhagic shock demonstrated conclusive protective effects after the HES 130 infusion. This result is consistent with previous studies in other models [38, 39] and clinical cardiac surgery [40]. HES 130 inhibits the inflammatory response and NF-κB activation in a rat model of polymicrobial sepsis but GEL does not [38]. Varga et al. demonstrated that HES 130 prevents ischemia reperfusion-induced leukocyte reactions compared to GEL [39]. One or more protective mechanisms may come into play. Firstly, the animal peptide nature of GEL may render an enhanced immunogenicity compared to HES 130 [17]. Secondly, HES 130, but not GEL, exerts its protective effects via a direct interaction with the vascular endothelium and attenuates leukocyte-endothelial cell interactions [39]. HES 130 dampens HS/R-induced acute neutrophil tissue accumulation [15, 40].

The gut is a critical organ that is damaged by HS/R. The postischemic intestine releases proinflammatory molecules, such as superoxide radicals and cytokines, into the portal and systemic circulation, which produces gut-induced remote organ failure [41]. Previous reports have suggested a strong association between intestinal-reperfusion injury and acute damage to the lungs or liver [42‐44]. An infusion of HES 130 in this study inhibited the release of proinflammatory cytokines, such as TNF-α and IL-6, which are responsible for gut barrier dysfunction after HS/R [45, 46]. This result suggests a protective effect on gut barrier integrity, which reduced the levels of oxidative stress and inflammatory response in the liver, lungs and brain, and the occurrence of MOF. Additional studies on the long-term effects of resuscitation fluids should clarify whether HES 130 can prevent MOF.

Despite the Advanced Trauma Life Support course recommendations of lactated Ringer's solution, a strong case can be made for the use of colloids for initial resuscitation in austere settings, such as battlefield care, in which volume is necessarily limited. Actually, some colloid solutions have been recommended in the resuscitation of hemorrhagic shock in Tactical Combat Casualty Care [18, 47, 48].

The severity of HS was determined by bled volume and BE in this experiment. BE is an expedient and sensitive measure of both the degree and duration of hypoperfusion [49‐51]. It could be a useful guide to volume replacement in the resuscitation of trauma patients and endpoints of resuscitation [52‐54].

Our study has some limitations. The comparison results were obtained based on a rat volume-controlled model, which is modified to be more representative of traumatic hemorrhage, and need to be verified in a clinical study. Moreover, the maximal inflammatory and oxidative reaction seems to occur within two hours post-resuscitation in most studies [55, 56]. The present study examined only a single time point, that is, two hours after treatment. Thus, further studies about the long-term effects of these colloid solutions, especially the impact on organ function, are needed.

The current experimental data indicate that resuscitation after hemorrhagic shock with HES 130 attenuated oxidative stress and the inflammatory response in tissues following HS/R compared to HES 200 and GEL. No significant differences in oxidative stress and the inflammatory response were observed after 33 mL/kg HES 200 and GEL infusions. However, the efficacy of these colloids must be proved in the clinical arena. Therefore, further randomized trials are required.